logo
Plus   Neg
Share
Email

NextEra Energy's Financial Expectations Remain Unchanged - Quick Facts

NextEra Energy, Inc. (NEE) said it continues to project adjusted earnings per share compound annual growth rate to be in a range of 6% to 8% through 2021, off the 2018 adjusted earnings per share of $7.70, plus accretion of $0.15 and $0.20 in 2020 and 2021, respectively, from the Florida acquisitions.

For 2020, NextEra Energy continues to expect adjusted earnings per share to be in the range of $8.70 to $9.20.

For 2022, NextEra Energy expects to grow 6% to 8%, off 2021 adjusted earnings per share, to be in a range of $10.00 to $10.75 per share.

On an adjusted basis, NextEra Energy's full-year 2019 earnings were $8.37 per share, compared to $7.70 per share, in 2018, a year-over-year growth in adjusted earnings per share of approximately 8.7%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted approval for Coagulation Factor VIIa (Recombinant) to biopharmaceutical company LFB S.A. for the treatment and control of bleeding episodes occurring in adults and adolescents - 12 years of age and older- with hemophilia A or B with inhibitors. It is marketed as Sevenfact by LFB. Chipotle Mexican Grill, Inc. is giving away 100,000 burritos to healthcare workers, who are at present fighting in the front line against coronavirus or Covid-19 pandemic. The food chain has asked healthcare teams to submit their application by Thursday, April 2, which is this year's National Burrito day. The offer is valid for a free preconfigured Burritos by the Box order of 25 burritos. The U.S. Food and Drug Administration has urged to withdraw Sanofi's heartburn drug Ranitidine as well as its generics from the market with immediate effect for possible contamination. The recall involves all prescription and over-the-counter or OTC ranitidine drugs, commonly known by the brand name Zantac. The recall includes generic products that contain ranitidine made by Novartis, Endo...
Follow RTT
>